Ergothioneine and associated nutraceutical compounds exhibit inherent bitterness and offensive odors. Eliminating these sensory barriers increases consumer compliance and product viability.

Natural ergothioneine compounds possess inherent bitterness and metallic notes that limit consumer compliance in oral delivery formats. Overcoming these sensory barriers allows for higher therapeutic dosages in non-clinical applications.

Ergothioneine and associated fatty acids exhibit inherent bitterness and malodorous properties that limit consumer acceptance. Neutralizing these sensory barriers allows for higher concentration formulations in oral products.

Excessive histamine activity prevents restorative sleep cycles. Regulating this biochemical pathway mitigates physiological wakefulness triggers.